Alembic Pharmaceuticals' Q2 profit rose 81% to about Rs 335 crore as US formulations sales grew 77% to Rs 1,003 crore.
Results · Finvezto · 4 Nov 2026 · Alembic Pharmaceuticals (APLLTD)
Results Q2 FY27, ₹ Cr
| Q2 FY27 | ₹ Cr | QoQ | YoY |
|---|---|---|---|
| Revenue | 2,604 | +21.1% | +36.3% |
| Operating profit | 563 | +69.7% | +78.4% |
| Net profit | 334 | +93.7% | +81.8% |
| Operating margin | 21.6% | +6.2 pp | +5.1 pp |
| Net margin | 12.8% | +4.8 pp | +3.2 pp |
Key points
- Alembic Pharmaceuticals Limited reported consolidated revenue from operations of Rs 2,603 crore for Q2 FY27, up 36% YoY, with EBITDA rising 78% to Rs 578 crore and Profit After Tax growing 81% to Rs 335 crore. NSE filing
- Growth was driven by US Formulations revenue surging 77% YoY to Rs 1,003 crore, supported by three new product launches during the quarter. NSE filing
- Revenue was ₹2,604 Cr, up 36.3% on a year earlier and up 21.1% on the quarter before. Finvezto data
Anand's note
Anand Ganapathy K: Revenue rose 36% to Rs 2,603 crore, with three US launches in the quarter. The shares hit their 20% upper circuit on 4 November. Source: Stock note
What to watch
- Operating margin over the last 4 quarters (Dec 25, Mar 26, Jun 26, Sep 26): 15.6%, 12.3%, 15.4%, 21.6%.
- Net profit over the last 4 quarters (Dec 25, Mar 26, Jun 26, Sep 26), ₹ Cr: 132, 202, 172, 334.
Links
NSE filing (PDF) · Company page · Results tracker
Anand Ganapathy K | SEBI Registered Research Analyst | INH000016630.